CO-LIQID-INC.
22.6.2022 17:32:06 CEST | Business Wire | Press release
LIQID Inc., one of the world’s leading software companies delivering data center composability, announced today a new case study with Durham University in Durham, England, describing its deployment of Liqid composable disaggregated infrastructure (CDI) software. Durham University is home to the COSmology MAchine (COSMA) operated by the Institute for Computational Cosmology (ICC) and is a national supercomputing facility that is part of the UK’s Distributed Research utilizing Advanced Computing (DiRAC) system. Liqid Matrix™ CDI software is part of a system used to study the origins of the universe, composing disaggregated GPUs in a tight footprint designed for a more sustainable digital architecture. With the ability to grow as resources are needed, the Liqid system will help researchers in the UK and around the world unlock the mysteries of the 14 billion-year history of the cosmos with far greater speed and efficiency than traditional data center systems.
“We are honored to work with institutions like Durham University and COSMA researchers to provide the resources to better explore the most profound questions in science,” said Sumit Puri, CEO & Cofounder, Liqid. “By providing the kind of software-defined data performance and architectural flexibility for powerful GPU, Liqid is enabling research breakthroughs that would have been impossible with traditional, static data center architectures so scientists can focus on results instead of waiting for resources and performance to become available.”
Liqid Matrix CDI Delivers Big Bang for Cosmologists with Adaptive, Efficient Architecture
“Durham University is using cutting-edge CDI to accelerate research, improve resource utilization, and reduce the university’s carbon footprint,” said Alistair Basden, technical manager for the DiRAC Memory Intensive Service at Durham University, who was interviewed for the case study entitled Durham University’s Institute for Computational Cosmology Accelerates Results with Composability from Liqid .
The COSMA memory-intensive system is designed specifically to support the largest cosmological simulations, most notably running simulations starting with the Big Bang and propagating through the entire history of the universe. Each simulation of dark matter, dark energy, black holes, galaxies and other structures in the universe often takes months to run, followed by long periods of data analysis.
While all of the applications deployed by DiRAC are memory intensive, valuable GPU resources are required for some of its most challenging simulations and analysis. Durham University chose Liqid Matrix software-based composable system in order to be able to share and scale GPUs in the exact amounts required for any given workload. Once the workload has been completed, GPU resources can be redistributed through Liqid Matrix software for use by other applications.
“It would be wasteful for us to populate all our nodes with GPUs,” Basden said in an interview for the case study. “Instead, we have some fat compute nodes and a login node, and we’re able to move GPUs between those systems. Composing our GPUs gives us flexibility with a smaller number of GPUs. We can individually populate the servers with one or more GPUs as required at the click of a button.”
Durham University IT is also deploying Liqid Matrix-based systems as an element of its overall strategy for a more sustainable IT ecosystem. Software-based composability enables users to do more with less, increasing efficiency and curtailing the need for physical space to store the hardware while providing significant reductions in cooling and water requirements.
“Rather than populating all our servers with GPUs, we can compose the resources we need to each server. That reduces our carbon footprint,” said Basden.
To learn more about Liqid’s academic deployments, review Liqid’s case study outlining the company’s work with the University of Illinois at Chicago’s Electronic Visualization Laboratory . Schedule an appointment with an expert on solutions based on Liqid Matrix ™ CDI software-based and set up a free infrastructure evaluation by going here. Follow Liqid on Twitter and LinkedIn to stay up to date with the latest Liqid news and industry insights.
About Liqid Inc.
Liqid’s composable infrastructure software platform, Liqid Matrix ™, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure. Now IT professionals can configure, deploy, and scale physical, bare-metal servers in seconds, then reallocate valuable accelerator and storage resources via software as needs evolve. Dynamically provision previously impossible systems or scale existing investments, and then redeploy resources where needed in real-time. Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005323/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
